^
Association details:
Biomarker:IGH mutation + Chr del(11q)
Cancer:Chronic Lymphocytic Leukemia
Regimen: (cyclophosphamide + fludarabine IV + Rituxan (rituximab))
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

001 | TOWARDS CONTROL OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH TARGETED AGENTS

Published date:
06/09/2021
Excerpt:
...FCR treatment of CLL patients with the combined occurrence of mutated IGHV genes plus del(13q), del(11q) or trisomy 12 yielded an overall survival rate above 90% at 5 years.